Introduction: Esophageal cancer is an aggressive neoplasm associated with high mortality and often late diagnosis. It represents the seventh most common type of cancer worldwide and the sixth leading cause of cancer-related death, with approximately 604,000 new cases and 544,000 deaths globally in 2020. In Brazil, both incidence and mortality rates remain significant, particularly among populations exposed to risk factors such as smoking, alcohol consumption, and the ingestion of very hot foods. Early clinical manifestations are subtle, but rapid progression to severe dysphagia makes this tumor a major cause of emergency hospitalizations. Given its high lethality, the need for emergency surgical or palliative management, and the associated costs, epidemiological analysis of esophageal cancer hospitalizations in the public healthcare system is essential to support intervention strategies and optimize healthcare resources. Objectives: To evaluate the trends in mortality rates and the average hospitalization costs for patients with malignant esophageal neoplasms across Brazilian regions between 2020 and 2024. Methods: This is a descriptive, quantitative study using data from the Hospital Information System (SIH/SUS) available on DATASUS. The variables analyzed included year of processing, state unit, type of admission, average AIH cost, and mortality rate. Results: Between 2020 and 2024, the mortality rate for esophageal neoplasms in Brazil was 16.08%, with annual variations ranging from 15.10% to 16.65%. A progressive increase was observed from 2020 (15.10%) to 2022 (16.65%), followed by a slight decrease in 2023 (16.53%) and 2024 (15.86%). The Northern region had the highest mortality rate at 18.03%, whereas the Southern region showed the lowest rate at 13.08%. Additionally, the nature of the hospitalization significantly influenced outcomes: emergency admissions had a mortality rate of 18.76%, nearly double that of elective admissions (9.11%). The average AIH cost for esophageal malignant neoplasm hospitalizations in Brazil was R$1,723.57. Regionally, the North had the lowest average cost per hospitalization at R$1,558.57, while the South recorded the highest cost at R$1,841.41. Conclusion: It can be inferred that malignant esophageal neoplasms remain a costly condition for the public healthcare system. Regionally, it was noted that the North, despite having the highest mortality rate, had the lowest hospitalization cost. Conversely, the South, with the lowest mortality rate, had the highest average hospitalization cost. These findings suggest significant economic disparities in the management of patients with malignant esophageal neoplasms, resulting in differing clinical outcomes across regions and highlighting the need to develop strategies aimed at reducing mortality rates in areas with fewer healthcare resources.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
